Weight change associated with the use of migraine-preventive medications

被引:33
|
作者
Taylor, Frederick R. [1 ,2 ]
机构
[1] Pk Nicollet Headache Clin & Res Ctr, Minneapolis, MN 55426 USA
[2] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA
关键词
antiepileptics; beta-adrenergic-receptor blockers; migraine preventive; tricyclic antidepressants; weight change;
D O I
10.1016/j.clinthera.2008.06.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Medications administered long term, such as those used for migraine prophylaxis, are often associated with weight change as a side effect. Such effects may compromise general health status, exacerbate coexisting medical conditions, and affect medication adherence. Weight gain should be of particular concern in patients with migraine, as there is evidence that overweight and obese patients with migraine are at risk for an increased frequency and severity of migraine attacks. Objective: This article reviews weight-change data from recent clinical studies of migraine-preventive medications in children, adolescents, and adults with migraine. Methods: A PubMed search was conducted for English-language articles published between January 1970 and November 2007. Among the search terms were migraine prevention, migraine prophylaxis, migraine treatment, antidepressant drug, beta-adrenergic-receptor blockers, antiepileptic drug, anticonvulsant drug, weight gain, and weight loss. Studies that reported weight-change data (gain, loss, or neutral) were included. When available, double-blind, placebo-controlled studies were selected for review. Open-label, retrospective or prospective trials may also have been included. Results: Most of the migraine-preventive medications classified by the United States Headache Consortium as group 1 based on the high level of evidence for their efficacy-for instance, amitriptyline, propranolol, and divalproex sodium-have been associated with varying degrees of weight gain. The exceptions are timolol, which is weight neutral, and topiramate, which is associated with weight loss. Among the drugs that have been associated with weight gain, a higher incidence of weight gain was observed with amitriptyline and divalproex sodium than with propranolol. Conclusion: Weight-change effects require careful consideration when selecting migraine-preventive medications, and weight should be monitored carefully over the course of any migraine treatment plan.
引用
收藏
页码:1069 / 1080
页数:12
相关论文
共 50 条
  • [41] The Use of Pharmacological Preventive Therapy for Migraine With Weight Gain Potential Amid Coronavirus Disease 2019 Pandemic
    Kow, Chia Siang
    Hasan, Syed Shahzad
    HEADACHE, 2020, 60 (09): : 2085 - 2086
  • [42] Antidepressant Medications and Weight Change: A Narrative Review
    Gill, Hartej
    Gill, Barjot
    El-Halabi, Sabine
    Chen-Li, David
    Lipsitz, Orly
    Rosenblat, Joshua Daniel
    Van Rheenen, Tamsyn E.
    Rodrigues, Nelson B.
    Mansur, Rodrigo B.
    Majeed, Amna
    Lui, Leanna M. W.
    Nasri, Flora
    Lee, Yena
    Mcintyre, Roger S.
    OBESITY, 2020, 28 (11) : 2064 - 2072
  • [43] Reductions in medical and pharmacy resource utilization associated with "Triptan" and preventive medication initiation in migraine patients previously naive to both medications
    Winner, PK
    Cramer, JA
    Reed, RC
    Silberstein, SD
    Chmiel, JJ
    Noble, KJ
    ANNALS OF NEUROLOGY, 2000, 48 (03) : 498 - 499
  • [44] Is 10 year weight change associated with use of supplements marketed for weight management?
    Nachtigal, MC
    Stratton, KL
    White, E
    Patterson, RL
    JOURNAL OF INVESTIGATIVE MEDICINE, 2004, 52 (01) : S96 - S96
  • [45] MSQ Utility Mapping of Rimegepant by Change in Monthly Migraine Days for Preventive Treatment of Migraine
    Johnston, Karissa
    L'Italien, Gilbert
    Popoff, Evan
    Powell, Lauren
    O'Sullivan, Fiona
    Harris, Linda
    Croop, Robert
    Coric, Vlad
    Lipton, Richard B.
    NEUROLOGY, 2022, 98 (18)
  • [46] Comparison of Onabotulinumtoxin A with other preventive medications (amitriptyline, topiramate and candesartan) in the management of chronic migraine
    Heydarova, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 629 - 629
  • [47] Exploratory efficacy of INP104 in patients using concomitant preventive migraine medications
    Grant, J.
    Vann, R.
    Fitzpatrick, C.
    Lieu, T.
    Shrewsbury, S. B.
    Aurora, S. K.
    HEADACHE, 2022, 62 : 147 - 148
  • [48] Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis
    Peterlin, B. Lee
    Bond, Dale S.
    Ailani, Jessica
    Dodick, David W.
    Liu, Yingyi
    Ferreira, Rosa De Abreu
    Smith, Jonathan H.
    Dabruzzo, Brett
    Goadsby, Peter J.
    Trugman, Joel M.
    CEPHALALGIA, 2024, 44 (12)
  • [49] Genetics of weight gain associated with antipsychotic medications
    Mueller, D. J.
    Peter, C.
    Puls, I.
    Brandl, E. J.
    Lang, U. E.
    Gallinat, J.
    Heinz, A.
    NERVENARZT, 2009, 80 (05): : 556 - 563
  • [50] WEIGHT CHANGE AND DIABETES MEDICATIONS: IS THERE AN ASSOCIATION WITH ADHERENCE AND DISCONTINUATION?
    Boye, K.
    Shinde, S.
    Kennedy-Martin, T.
    Robinson, S.
    Thieu, V. T.
    VALUE IN HEALTH, 2022, 25 (01) : S220 - S220